SCHEMBL203845

SCHEMBL203845

CC1(C(=O)Nc2ccc(C#N)cc2)CC([Si](C)(C)C)N=N1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PGR P06401 3/20 0.42
SAE1 Q9UBE0 1/20 0.41
UBA2 Q9UBT2 1/20 0.41
EPHX1 P07099 1/20 0.40
MAPT P10636 3/20 0.39
ALDH1A1 P00352 3/20 0.39
MEN1 O00255 2/20 0.39
KMT2A Q03164 2/20 0.39
LMNA P02545 3/20 0.39
TSHR P16473 1/20 0.39
HTT P42858 1/20 0.39
NLRP3 Q96P20 1/20 0.39
BRD4 O60885 1/20 0.39
CREBBP Q92793 1/20 0.39
EPHX2 P34913 1/20 0.38
KDM4E B2RXH2 1/20 0.38
POLB P06746 1/20 0.38
PKM P14618 1/20 0.38
MAPK1 P28482 1/20 0.38
RAB9A P51151 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2702503 0.81 BACE1 (0.32) LMNATSHRPOLBSMN1; SMN2
SCHEMBL202831 0.80 AR (0.45)
SCHEMBL1168058 0.68 EPHX1 (0.50) PGRSAE1UBA2EPHX1MAPT
SCHEMBL20941561 0.68 SAE1 (0.56) PGRSAE1UBA2EPHX1MAPT
SCHEMBL204920 0.68 SAE1 (0.43) PGRSAE1UBA2EPHX1MAPT
SCHEMBL431681 0.68 EPHX1 (0.44) PGRSAE1UBA2EPHX1MAPT
SCHEMBL1167839 0.67 PGR (0.46) PGRSAE1UBA2EPHX1MAPT
SCHEMBL202289 0.66 SAE1 (0.43) PGRSAE1UBA2EPHX1MAPT
SCHEMBL2585205 0.66 MAPT (0.50) PGRSAE1UBA2EPHX1MAPT
SCHEMBL16512510 0.64 MAPT (0.49) PGRSAE1UBA2EPHX1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8088811-B2 Heterocycle derivatives useful as selective androgen receptor modulators (SARMs) JANSSEN PHARMACEUTICA N.V. (BE) 2012-01-03 US disclosed
US-7781473-B2 Heterocycle derivatives useful as selective androgen receptor modulators (SARMS) J & J Pharmaceutical Research & Development, LLC. (US) 2010-08-24 US disclosed
US-20090131365-A1 NOVEL HETEROCYCLE DERIVATIVES USEFUL AS SELECTIVE ANDROGEN RECEPTOR MODULATORS (SARMS) ZHANG XUQING 2009-05-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090131365-A1 NOVEL HETEROCYCLE DERIVATIVES USEFUL AS SELECTIVE ANDROGEN RECEPTOR MODULATORS (SARMS) AR, NR5A1, NR5A2 PGR 61/4885SAE1 1521/4885UBA2 1375/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.